Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/785—Polymers containing nitrogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/722—Chitin, chitosan
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent"), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation.
• the invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.
• TLRs are type I transmembrane proteins composed of an extracellular domain of leucine-rich repeats and an intracellular Toll/interleukin-1 (IL-1) receptor (TIR) domain (Leulier and Lemaitre, Nat. Rev. Genet. 9: 165-178 (2008)).
• IL-1-1 receptor (TIR) domain Toll/interleukin-1 receptor (IL-1) receptor (TIR) domain.
• TIR Toll/interleukin-1 receptor
• TLR2, 4, 5, 6 and 1 1 bind to bacterial outer membrane molecules such as lipopolysaccharide (LPS), peptidoglycan and lipoteic acid while TLR3, TLR7, TLR8 and TLR9 recognize bacterial, viral or even endogenous nucleic acids ( awai and Akira, Semin.
• LPS lipopolysaccharide
• TLR8 and TLR9 recognize bacterial, viral or even endogenous nucleic acids ( awai and Akira, Semin.
• TLRs can be classified based on their cellular localization: TLRl , 2, 4, 5 and 6 are expressed on the cell surface while TLR3, 7, 8 and 9 are localized mostly, though not exclusively, in endosomal compartments (Kawai and Akira, Semin. Immunol. 19:24-32 (2007)).
• TLR activation initiates intracellular signaling events that result in the expression of immune response genes including inflammatory and immune modulatory cytokines, chemokines, immune stimulatory receptors, which augments killing of pathogens and initiates the process of developing acquired immunity (Takeda and Akira, Int. Immunol. 17: 1- 14 (2005), Akira et al, Cell 124:783-801 (2006)).
• TLRl TLR2, TLR3, TLR4 and TLR9
• TLRl bacterial sepsis
• TLR4 non-infection systemic inflammatory response syndrome
• TLR9 inhibitor inhibitory CpG DNA
• an antagonistic anti-TLR3 antibody Cavassani et al, J. Exp. Med. 205:2609-2621 (2008)
• Oligonucleotide-based TLR7 and TLR9 inhibitors prevented IFNa production from human plasmacytoid dendritic cells stimulated with serum from SLE patients (Barrat et al, J. Exp. Med. 202: 1 131-1 139 (2005)). Unfortunately, the redundancy of the TLR family may limit the utility of inhibitors that target individual TLRs.
• TLRs Upon stimulation, all TLRs recruit intracellular TIR-domain-containing adapters, such as TRIF and MyD88 (Kawai and Akira, Semin. Immunol. 19:24-32 (2007)). These adapter molecules mediate a downstream cascade of TLR- associated signaling. TRIF is recruited to TLR3 and TLR4, and appears to activate IRF3, MAPK, and NF- ⁇ while MyD88 is associated with all TLRs, except TLR3, and phosphorylates IRAK, IRF5, IRF7, MAPK and NF- ⁇ , which enhance the expression of type I IFN, inflammatory cytokine and IFN-inducible genes (Kawai and Akira, Semin. Immunol. 19:24-32 (2007)).
• TIR-domain-containing adapters such as TRIF and MyD88 (Kawai and Akira, Semin. Immunol. 19:24-32 (2007)).
• endosomal TLRs Unlike other TLRs, endosomal TLRs, TLR3, 7, 8 and 9, all recognize microbial or host nucleic acids, as PAMPs or DAMPs, respectively.
• PAMPs microbial or host nucleic acids
• DAMPs DAMPs
• oligonucleotide-based drugs e.g., aptamers
• immune stimulatory siRNA a TLR7 agonist, condensed with a cyclodextrin-based polymer has been shown not to activate TLR7 (Hu-Lieskovan et al, Cancer Res. 65:8984-8992 (2005)).
• the present invention results, at least in part, from studies designed to determine whether agents that bind DNAs and RNAs in a sequence-independent manner (e.g., nucleic acid-binding cationic polymers) can neutralize endosomal TLR ligands and thereby inhibit activation of the corresponding TLRs.
• agents that bind DNAs and RNAs in a sequence-independent manner e.g., nucleic acid-binding cationic polymers
• the present invention relates generally to PRRs, including TLRs (e.g., endosomal TLRs). More specifically, the invention relates to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid ("nucleic acid binding agent"), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid responsible for inducing TLR activation.
• the invention further relates to methods of controlling inflammatory and/or autoimmune responses resulting from nucleic acid-induced receptor (e.g.
• the invention further relates to methods of identifying nucleic acid binding agents suitable for use in such methods.
• FIG. 1 A The murine macrophage cell line, Raw264.7 was co-incubated in a 24-well microplate with a TLR9 agonist (CpG) (2 ⁇ ), a TLR3 agonist (poly I:C) (10 ⁇ ) or a TLR4 agonist (LPS) (100 ng/ml) along with the cationic polymers, CDP, HDMBr, PAMAM, poly L-lysine or protamine (20 ⁇ g/ml) or PBS. Unmethylated GpC ODNs were used as a negative control for CpG.
• CpG TLR9 agonist
• poly I:C poly I:C
• LPS TLR4 agonist
• Unmethylated GpC ODNs were used as a negative control for CpG.
• Fig. 1 B The treated cells were tested for their expression of the co-stimulatory molecule CD86 using FACS.
• the light blue line represents PBS-treated cells.
• Green and red lines represent GpC- and CpG-treated cells, respectively.
• FIGS. 2A and 2B Timing of cationic polymer mediated inhibition of TLR activation.
• FIG. 2A Cells were incubated with CpG (2 ⁇ ) in a 24-well microplate. CDP (20 ⁇ g/ml) was added at 0, 1 ⁇ 2, 1 , 2, 4, 8 or 12 hours following the addition of CpG. At 24 hours after CpG treatment culture supematants were collected and analyzed for TNFa and IL-6 production.
• FIG. 2B Cells were pre- incubated for 1 or 2 hours with CDP or PBS, washed three times with complete medium and then incubated in culture media supplemented with CpG.
• TLR3 and TLR9 activation 1 x 10 6 Raw264.7 cells were cultured for 18 hours with either CpG (1 ⁇ ) (Fig. 3 A) or poly I:C (10 ⁇ g/ml) (Fig. 3B) in the presence or absence of CDP ( ⁇ ), HDMBr ([3 ⁇ 4) or PAMAM ( ⁇ ) at the indicated
• FIG. 4A TLR3- or TLR9-mediated acute liver inflammation can be alleviated by nucleic acid-binding polymers.
• FIG. 4 A Mice (5-10
• mice/group were i.p. injected with D-GalN (20 mg) alone, CpG (51 ⁇ g) alone, D- GalN + GpC (51 ⁇ g) or D-GalN + CpG (51 ⁇ g).
• D-GalN 20 mg
• CpG 51 ⁇ g
• D- GalN + GpC 51 ⁇ g
• D-GalN + CpG 51 ⁇ g
• PBS 100 ⁇
• CDP 200 ⁇ g; blue diamond
• HDMBr 200 or 400 ⁇ g; red triangle
• PAMAM 200 or 400 ⁇ g; green rectangle
• FIG. 4B Mixture of Poly I:C (200 ⁇ g) and D-GalN (20 mg) in PBS (100 ⁇ ) was injected i.p. into mouse (5 mice/group). Subsequently, PBS (100 ⁇ ; black circle), CDP (400 or 800 ⁇ g; blue diamond), HDMBr (200 or 400 ⁇ g; red triangle) or PAMAM (200 or 400 ⁇ g; green rectangle) was injected i.p. There is 5-10 minutes interval between injections.
• FIG. 4C Mice were injected with PBS, CpG + D- GalN or CpG + D-GalN + CDP.
• FIG. 5A and 5B Stoichiometry of TLR inhibition of CDP.
• Raw264.7 cells were cultured for 18 hours with either CpG (1 ⁇ , 2 ⁇ , 4 ⁇ , 8 ⁇ ) (Fig. 5 ⁇ ) or poly I:C (10 ⁇ g/ml or 25 ⁇ g/ml) (Fig. 5B).
• TLR ligands were simultaneously supplemented with CDP at various concentration (0, 4, 8, 12, 16, 20, 24, 36, 48 ⁇ for CpG; 0, 10, 20, 30,40, 80, 160 ⁇ for poly I:C).
• Amount of TNFa was measured by ELISA. % inhibition was calculated by ([CpG or poly I:C] - [CpG or poly I:C + CDP]) / [CpG or poly I:C] x 100.
• FIG. 6 Cellular toxicity of cationic molecules. 1 x 10 6 Raw264.7 cells were cultured for 24 hours with CDP (black), HDMBr (red), PAMAM (blue), PPA-DPA (green), protamine (gray) or poly L-lysine (purple) at various concentration (10, 20, 40, 80, 160, 280, 400 and 600 ⁇ ). Viability of cells was analyzed using hematocytometer after staining with trypan blue (Sigma, St. Louis, MO).
• FIGS. 7A-7D CDP enhanced CpG uptake of cells.
• Raw264.7 cells (1 x 10 5 cells/well) were cultured overnight in 8-well chamber slide (Nalge Nunc International Corp, Naperville, IL). After thrice washing with cold complete media, cells were replenished with fresh complete media including 1 ⁇ of CpG conjugated with 6-FAM at 5' end with or without 10 ⁇ g/ml of CDP. Cells were incubated for 1 (Figs. 7A and 7C) or 2 hours (Figs. 7B and 7D) at either 4 °C or 37°C. Fluoresce signals were observed with the Olympus 1X71 Inverted
• PRRs are a pivotal component of host immune cells to protect tissues from various harmful stimuli, such as pathogens and damaged cells.
• a variety of PRRs including RIG-I-like receptors (RLRs), dsRNA-dependent protein kinase R (P R), DNA-dependent activator of IRFs (DAI) and TLRs can recognize diverse products of pathogens and damaged cells that are referred to PAMPs and DAMPs (Lotze et al, Immunol. Reviews 220:60-81 (2007)).
• TLRs play a central role in host innate and acquired immunity, as well as in the pathogenesis of various diseases, including infectious diseases,
• TLRs 3, 7, 8 and 9 are localized in endosomes can be activated by microbial and host nucleic acids.
• the present invention relates, in one embodiment, to a method of inhibiting nucleic acid-induced activation of endosomal TLRs.
• the method comprises administering to a patient in need thereof an agent that binds nucleic acids responsible for induction of TLR activation in an amount and under conditions such that inhibition of that activation is effected.
• the agent binds the nucleic acids in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example, a protein) of the nucleic acids responsible for inducing TLR activation.
• the present method can be used to treat inflammatory and/or autoimmune responses resulting from endosomal activation.
• Nucleic acid binding (scavenging) agents of the invention include pharmaceutically acceptable member(s) of a group of positively charged compounds, including proteins, lipids, and natural and synthetic polymers, that can bind nucleic acids in, for example, biologically fluids.
• Proteinaceous nucleic acid binding agents of the invention include protamines, a group of proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish, such as salmon.
• Nucleic acid binding agents of the invention also include protamine variants (e.g., the +18RGD variant (Wakefield et al, J. Surg. Res. 63:280 (1996)) and modified forms of protamine, including those described in Published U.S. Application No. 20040121443.
• Other nucleic acid binding agents of the invention include protamine fragments, such as those described in USP 6,624,141 and U.S. Published Application
• Nucleic acid binding agents of the invention also include, generally, peptides that modulate the activity of heparin, other
• the invention further includes pharmaceutically acceptable salts of the above- described nucleic acid binding agents, as appropriate, including sulfate salts.
• Proteinaceous nucleic acid binding agents of the invention also include DNA and/or RNA reactive antibodies.
• anti-nuclear antibodies such as those indicative of lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, autoimmune hepatitis, scleroderma, polymyositis and dermatomyositis, can be used.
• Specific examples of antibodies that recognize RNA/DNA include those described by itagawa et al (Mol. Immunol. 19(3):413-20 (1982)),
• heterogeneous nuclear ribonucleoproteins can also be used in accordance with the invention.
• Cationic peptides that bind nucleic acids are suitable for use.
• a chimeric peptide synthesized by adding nonamer arginine residues at the carboxy terminus of RVG has been described by Kumar et al (Nature 448:39-43 (2007)).
• Viral proteins that package (e.g., coat) DNA or RNA (e.g., HIV gag protein), and peptides derived therefrom, can also be used in the present methods.
• Cationic lipids can also be used as nucleic acid binding agents in accordance with the invention.
• Suitable cationic lipids include those described by Morille et al (Biomaterials 29:3477 (2008)) (e.g., linear poly(ethyleneimine) (PEI), poly(L-lysine) (PLL), poly(amidoamine) (PAMAM) dendrimer generation 4, chitosan, DOTMA, DOTAP, DMRIE, DOTIM, DOGS, DC-Choi, BGTC and DOPE).
• Nucleic acid binding agents of the invention also include intercalating agents. Examples include ethidium bromide, proflavine, daunomycin, doxorubicin and thalidomide. Nucleic acid binding porphyrins can also be used in accordance with the invention (see Table 1).
• Preferred nucleic acid binding agents of the invention include polycationic polymers.
• Preferred polycationic polymers include biocompatible polymers (that is, polymers that do not cause significant undesired physiological reactions) that can be either biodegradable or non-biodegradable polymers or blends or copolymers thereof.
• polymers include, but are not limited to, polycationic biodegradable polyphosphoramidates, polyamines having amine groups on either the polymer backbone or the polymer side chains, nonpeptide polyamines such as poly(aminostyrene), poly(aminoacrylate), poly(N-methyl aminoacrylate), poly(N-ethylaminoacrylate), poly(N,N-dimethyl aminoacrylate), poly(N,N-diethylaminoacrylate), poly(aminomethacrylate), poly(N-methyl amino-methacrylate), poly(N-ethyl aminomethacrylate), poly(N,N-dimethyl aminomethacrylate), poly(N,N-diethyl aminomethacrylate), poly(ethyleneimine), polymers of quaternary amines, such as poly( ,N,N-trimethylaminoacrylate chloride), poly(methyacrylamidopropyltrimethyl ammonium chloride); natural or synthetic polysaccharides such as poly
• Nucleic acid binding agents of the invention can include compounds of types described in Table 1 , or derivatives thereof. Several of the compounds described in Table 1 contain cationic-NH groups permitting stabilizing charge- charge interactions with a phosphodiester backbone. Nucleic acid binding agents of the invention containing secondary amines can include, for example, 5-350 such groups (e.g., 5-300, 5-250, 5-200, 5-100, 5-50, 50-100, 50-200, 50-300, 50- 350, 100-200, 100-30.0, 100-350, 200-350, 200-300, or 250-350), and can have a molecular weight in the range of, for example, 2,000 to 50,000 (e.g., 10,000 to 50,000 or 20,000 to 40,000).
• 5-350 such groups
• the binding affinity of a nucleic acid binding agent of the invention for a nucleic acid is in the pM to ⁇ range, preferably, less than or equal to 50 nM; expressed in terms of binding constant ( ), the binding affinity is advantageously equal to or greater than 10 5 M “ ', preferably, 10 5 M “ ' to 10 8 M “ ', more preferably, equal to or greater than 10 6 M " ' .
• the binding affinity of the sequence-independent nucleic acid binding agents can be, for example, about 1 x 10 5 M ⁇ ⁇ 5 x 10 5 M " ⁇ 1 x 10 6 M ⁇ ', 5 x 10 6 M ⁇ ', 1 x 10 7 M “ ', 5 x 10 7 M “ '; or about 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 ⁇ , 10 ⁇ , 100 ⁇ .
• " " and “Kd” can be determined by methods known in the art, including surface plasmon resonance or a real time binding assay such as Biacore.
• Preferred nucleic acid binding agents of the invention simultaneously limit the activation of multiple endosomal TLRs (e.g., TLR3 and TLR9).
• TLR3 and TLR9 Particularly preferred are CDP or CDP-im, HDMBr and PAMAM (see USPs 7,270,808, 7,166,302, 7,091 ,192, 7,018,609, 6,884,789, 6,509,323, 5,608,015, 5,276,088, 5,855,900, U.S. Published Appln. Nos. 20060263435, 20050256071 ,
• the present invention provides a method of controlling (inhibiting or preventing) autoimmune and/or inflammatory responses associated with activation of TLRs (e.g., endosomal TLRs such as TLR3 and TLR9).
• TLRs e.g., endosomal TLRs such as TLR3 and TLR9
• Such responses play a role in the pathogensis of diseases/disorders that are associated with presence in the circulation of the patient of free nucleic acids, either pathogen-derived (e.g., viral- or bacterial-derived) nucleic acids or nucleic acids released from dead or damaged host cells.
• RLRs are a family of cytoplasmic RNA helicases including retinoic-acid- inducible protein I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA5).
• RIG-I recognize uncapped 5 '-triphosphate ssRNA and short dsRNA while MDA5 recognize long dsRNA (Pichlmair et al, Science 314:997-1001 (2006), Homung et al, Science 314:994-997 (2006), ato et al, J. Exp. Med. 205: 1601-1610 (2008)).
• Signaling of RLRs is initiated by interaction of caspase recruitment domain (CARD)-containing adapter molecule, IFNP promoter stimulator- 1 (IPS-1), and induce production of type I IFN and inflammatory cytokines (Kawai et al, Ann. N. Y. Acad. Sc. 1 143:1-20 (2008)).
• CARD caspase recruitment domain
• IPS-1 IFNP promoter stimulator- 1
• PKR is an IFN- inducible cytosolic enzyme and recognizes viral dsRNAs while DAI recognizes cytoplasmic dsDNA (Langland et al, Virus Res 1 19: 100-1 10 (2006), Takaoka et al, Nature 448:501 -505 (2007)).
• cytoplasmic PRRs including RIG-I, MDA5 and PKR, are able to recognize RNAs or DNAs and activation of these PRRs is associated with type I IFN production.
• cytoplasmic nucleic acid-sensing PRRs may also contribute to the pathogenesis of such diseases because signaling from these receptors robustly elicits production of IFN , one of the major pathogenic factors in a variety of inflammatory diseases (J. Banchereau et al, Immunity 20:539-550 (2004)).
• the present invention also relates a method of inhibiting nucleic-acid induced activation of these members of the PRR family using the approaches and agents described above.
• nucleic acid-binding agents scavengers
• scavengers nucleic acid-binding agents
• Another application of nucleic acid-binding agents (scavengers) described herein is to counteract the effects of DNA and RNA molecules that are released from cells and subsequently induce thrombosis (Kannemeier et al, Proc. Natl. Acad. Sci. 104:6388-6393 (2007); Fuchs et al, Proc. Natl. Acad. Sci. Published Online before Print August 23, 2010).
• RNA and DNA molecules can activate the coagulation pathway as well as platelets and thereby engender blood clotting (Kannemeier et al, Proc. Natl. Acad. Sci.
• nucleic acid binding agents (scavengers) described herein can bind RNA and DNA molecules and shield them from other potential binding partners, such agents can be employed to inhibit the ability of DNA and RNA molecules to bind and activate coagulation factors and platelets. In so doing, these RNA/DNA scavengers can be utilized to limit nucleic acid- induced pathological blood coagulation.
• nucleic acid binding agents (scavengers) described herein represent novel entities for preventing the induction and progression of a variety of thrombotic disorders including myocardial infarction, stroke and deep vein thrombosis.
• the nucleic acid binding agents of the invention can be administered to the patient via any route such that effective levels are achieved in, for example, the bloodstream.
• the optimum dosing regimen will depend, for example, on the nucleic acid binding agent, the patient and the effect sought.
• the nucleic acid binding agent will be administered orally, transdermally, IV, IM, IP or SC.
• the nucleic acid binding agent can also be administered, for example, directly to a target site, for example, directly to a tumor (e.g., a brain tumor) when cancer is the disease to be treated.
• the nucleic acid binding agent is administered as soon as clinical symptoms appear and administration is repeated as needed.
• nucleic acid binding agents including nucleic acid binding polymers incorporated into microparticles or nanoparticles or beads
• pharmaceutically acceptable salts thereof can be formulated with a carrier, diluent or excipient to yield a pharmaceutical composition.
• the precise nature of the compositions of the invention will depend, at least in part, on the nature of the nucleic acid binding agent and the route of administration. Optimum dosing regimens can be readily established by one skilled in the art and can vary with the nucleic acid binding agent, the patient and the effect sought.
• Proteinaceous nucleic acid binding agents of the invention can also be produced in vivo following administration of a construct comprising a sequence encoding the proteinaceous nucleic acid binding agent (Harrison, Blood Rev. 19(2): 1 1 1 -23 (2005)).
• the treatment methods of the present invention are useful in the fields of both human medicine and veterinary medicine.
• the patient (subject) to be treated can be a mammal preferably a human.
• the subject can be, for example, a farm animal such as a cow, pig, horse, goat or sheep, or a companion animal such as a dog or a cat.
• endosomal TLR-containing cells preferably, mammalian cells (e.g., mammalian macrophage cells in culture) are incubated with a first endosomal TLR agonist (e.g., CpG DNA or single or double stranded RNA or nucleic acid-containing particles) in the presence and absence of a test agent.
• a culture supernatant sample can be taken and analyzed for the presence of a product of an intracellular signaling event initiated by TLR activation, for example, one or more cytokines (e.g., TNFa and/or IL-6).
• cytokines e.g., TNFa and/or IL-6
• a test agent that inhibits endosomal TLR agonist activation preferably, in a manner independent of the sequence, chemistry and/or structure of the endosomal TLR agonist used, (that inhibition of activation being evidenced by inhibition of production of a product of an intracellular signaling event initiated by TLR activation (e.g., cytokine production) (e.g., in a dose dependent manner)) can then be tested in vivo, for example, in mice, to further assess its suitability for use in the methods described herein.
• TLR activation e.g., cytokine production
• the complete medium was supplemented with phosphorothioate B-type CpG DNA 1668 (5 ' -TCCATGACGTTCCTG ATGCT- 3'), a phosphorothioate GpC DNA 1720 (5 ' -TCCATGAGCTTCCTGATGCT-3 ') as a control CpG DNA (both from IDT, Coralville, IA) or a mimetic of viral dsRNA, poly I:C (Amersham/GE Healthcare, Piscataway, NJ) at various concentrations.
• Bacterial LPS serotype 026:B6 (100 ng/ml) (Sigma-Aldrich, Saint Louis, MO) activating TLR4 were used as a non-nucleotide-based TLR ligand.
• CDP Calando Pharmaceuticals, Pasadena, CA
• protamine APP, Schaumburg, IL
• PPA-DPA PAMAM
• Co-stimulatory molecule expression on macrophage 1 x 10 6 Raw264.7 cells were cultured with phosphate buffer saline (PBS), GpC DNA (2 ⁇ ) or CpG DNA (2 ⁇ ). To block binding of CpG DNA and TLR9 CDP, HDMBr, PAMAM, PPA-DPA, poly-L-lysine or protamine (20 ⁇ g/ml each) were co-treated with CpG DNA. After 18 hours, cells were detached from plates by treatment of
• TLR3 or TLR9-mediated acute liver injury in a D- galactosamine-sensitized mice was performed as previously described (Alexopoulou et al Nature 413:732-738 (2001), Duramad et al, J.
• C57BL/6 mice were injected intraperitoneally (i.p.) with PBS (100 ⁇ ), CpG DNA (25 to 51 ⁇ g), GpC DNA (50 ⁇ g) or poly I:C (50 to 200 ⁇ g) with or without D(+)Galactosamine,
• mice 1. p. Viability of mice was monitored for a week.
• Liver lobes were excised from mice 24 hours after injection of CpG + D-GalN with or without cationic molecules.
• the liver specimens were fixed with 4% formaldehyde, embedded in OCT and sectioned at a thickness of 20 ⁇ before staining with hematoxylin and eosin for light microscopic examination.
• Statistical Analysis The difference of cytokine production among experimental groups was compared by the paired two-tailed Student's t test analyzed with Microsoft Office Excel 2003. Significance of survival was determined by the log-rank test analyzed with GraphPad Prism® Version 4.0b. A probability of less than 0.05 (P ⁇ 0.05) was used for statistical significance.
• CDP ⁇ -cyclodextrin-containing polycation
• PPA-DPA polyphosphoramidate polymer
• PAMAM polyamidoamine dendrimer
• HDMBr hexadimethrine bromide
• poly I:Cs polyinosinic-polycytidylic acids
• TLR3 dsRNA activator of TLR3
• Fig. 1 A The CpG DNA- inhibitory cationic polymers also impeded the up-regulation of co-stimulatory molecules expressed on macrophages (Fig. I B).
• the inhibitors could be administered up to 4 hours after the CpG DNA and still significantly reduce TNFa and IL-6 production from macrophages (Fig. 2).
• the nucleic acid-binding polymers inhibit TLR3 and TLR9 activation in a dose-dependent manner.
• a dose-escalation study demonstrated that 8 to 12 ⁇ g/ml of the polymers, CDP, HDMBr and PAMAM, which inhibited the activation of both TLR3 and TLR9, can inhibit inflammatory cytokine production by greater than 95% from macrophages treated with CpG DNAs (1 ⁇ ) and 5 to 40 ⁇ g/ml of these same polymers can reduce cytokine production by greater than 95% from cells treated with poly I:C (10 ⁇ g/ml) (Figs. 3A and 5).
• Poly L-lysine and PPA-DPA induced over 50% cell death at approximately 20 and 40 ⁇ g/ml, respectively, while PAMAM, protamine and HDMBr induced over 50% cell death at about 160, 280 and 600 ⁇ / ⁇ , respectively.
• the CDP polymer was well tolerated on macrophages. In mice injected with the CDP, HDMBr and PAMAM at 40 mg kg, no adverse effects on viability were observed (data not shown).
• poly L-lysine and PPA-DPA have a relatively high cytotoxicity while PAMAM, HDMBr and CDP have much less toxicity in vitro and in vivo.
• mice Consistent with previous reports, greater than 90% of the mice died by 48 hours following administration of D-GalN and CpG DNA or poly I:C while none of the mice injected with D-GalN alone, CpG DNA alone or D-GalN and control GpC DNA died.
• administration of one of three different nucleic acid-binding polymers, CDP, HDMBr or PAMAM, immediately following D-GalN and CpG DNA or poly I:C resulted in significant protection of the animals in a dose-dependent manner and reduced mortality by almost 100% in several cases (Figs. 4 A and 4B). Histological examination of livers from treated mice also demonstrated that inflammation and associated hemorrhage were greatly reduced in the polymer treated animals (Fig. 4C).
• Cationic polymers are commonly used for gene or siRNA delivery and are designed to facilitate cellular internalization and endosomal escape (Morille et al, Biomaterials.29:3477-3496 (2008)). Because they traffic through the endosomal compartment, cationic lipids have been used to deliver siRNAs and immune stimulatory ssRNAs to activate endosomal TLR7 or TLR8 (Judge et al, Nat. Biotechnol. 23:457-462 (2005), Sioud, J. Mol. Biol. 348: 1079-1090 (2005)).
• nucleic acid-binding polymers can simultaneously limit the activation of multiple endosomal TLRs. As such, these polymers represent promising therapeutic agents for treating patients with inflammatory diseases and autoimmune diseases. Additional preclinical and clinical studies will evaluate this possibility.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Marine Sciences & Fisheries (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Hematology (AREA)
• Rheumatology (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Child & Adolescent Psychology (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Obesity (AREA)
• Dermatology (AREA)
• Pulmonology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=43759220

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (11)

Citations (14)

Family Cites Families (21)

• 2010
  • 2010-09-16 WO PCT/US2010/002516 patent/WO2011034583A2/en not_active Ceased
  • 2010-09-16 IN IN2345DEN2012 patent/IN2012DN02345A/en unknown
  • 2010-09-16 US US13/496,313 patent/US9468650B2/en active Active
  • 2010-09-16 CN CN2010800511149A patent/CN102639142A/zh active Pending
  • 2010-09-16 EP EP10817556.3A patent/EP2477641B1/en active Active
  • 2010-09-16 CA CA2774460A patent/CA2774460C/en active Active
• 2016
  • 2016-10-12 US US15/291,849 patent/US11617779B2/en active Active
• 2023
  • 2023-03-30 US US18/128,957 patent/US20230248805A1/en active Pending

Patent Citations (15)

Non-Patent Citations (46)

Also Published As

Similar Documents

Legal Events